MODICON 21
Clinical safety rating
cautionComprehensive clinical and safety monograph for MODICON 21 (MODICON 21).
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.
| Metabolism | Ethinyl estradiol undergoes hepatic CYP3A4-mediated hydroxylation and conjugation; norethindrone is reduced and conjugated in liver. |
| Excretion | Renal (80% as metabolites, 20% unchanged); biliary/fecal (minor, <5% total) |
| Half-life | Terminal elimination half-life: 12–18 hours; clinical context: steady-state reached after 3–5 days of daily dosing |
| Protein binding | Ethinylestradiol: 97% bound to albumin; Norethindrone: 80% bound to albumin and SHBG |
| Volume of Distribution | Ethinylestradiol: 2–4 L/kg; Norethindrone: 3–5 L/kg; large Vd indicates extensive tissue distribution |
| Bioavailability | Oral: 40–60% (first-pass metabolism reduces systemic availability) |
| Onset of Action | Oral: 24–48 hours for contraceptive effect (ovulation inhibition); rapid onset if used for emergency contraception (within 72 hours of unprotected intercourse) |
| Duration of Action | Oral: 24 hours for contraceptive effect (requires daily dosing); duration of emergency contraceptive effect: single dose covers one menstrual cycle |
| Molecular Weight | 310.4 |
One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for chronic kidney disease. Contraindicated in acute renal failure or severe renal impairment (GFR <30 mL/min) due to potential fluid retention and electrolyte disturbances. |
| Liver impairment | Contraindicated in acute hepatic disease, hepatic adenomas, or impaired liver function (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution; monitor liver function. |
| Pediatric use | Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal minors established; dose same as adults (one tablet daily for 21 days, then 7 days off). |
| Geriatric use | Not indicated for use in postmenopausal women. No specific dose adjustments for elderly due to lack of indication; consider increased risk of cardiovascular and thrombotic events in women over 35 who smoke. |
| 1st trimester | Contraindicated due to risk of cardiovascular and limb defects; non-contraceptive use not recommended. |
| 2nd trimester | Contraindicated due to risk of fetal harm; associated with urogenital anomalies and developmental toxicity. |
| 3rd trimester | Contraindicated due to risk of fetal harm; associated with urogenital anomalies and developmental toxicity. |
Clinical note
Comprehensive clinical and safety monograph for MODICON 21 (MODICON 21).
| Placental transfer | Crosses placenta; detectable in fetal tissues. Evidence of teratogenicity in humans. |
| Breastfeeding | Excreted in breast milk in small amounts; potential adverse effects on nursing infant. Generally not recommended during breastfeeding. Use alternative contraception methods. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | Modicon 21 is a combination oral contraceptive. First trimester: Epidemiologic studies have not shown an increased risk of birth defects with inadvertent exposure. Second and third trimesters: Use is not indicated during pregnancy; fetal and neonatal risks include cardiovascular and genitourinary anomalies, though data are limited and confounded by maternal condition. |
| Fetal Monitoring | No specific monitoring is indicated because Modicon 21 is not used during pregnancy. If exposure occurs, routine prenatal care is sufficient. |
| Fertility Effects | Modicon 21 suppresses ovulation and creates a cervical mucus barrier. Fertility returns to baseline upon discontinuation; no permanent impairment. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day); women >35 years who smoke should not use this product.
| Serious Effects |
Known or suspected pregnancyHepatic adenoma or carcinomaUndiagnosed abnormal genital bleedingBreast cancerThromboembolic disordersCerebrovascular diseaseCoronary artery diseaseHypersensitivity to any component
| Precautions | Thrombotic disorders (thrombophlebitis, venous thromboembolism, arterial thromboembolism), Cardiovascular disease (e.g., myocardial infarction, stroke) especially in smokers >35, Liver disease (e.g., hepatic adenoma, hepatocellular carcinoma), Elevated blood pressure, Gallbladder disease, Carbohydrate/lipid metabolic effects, Ocular lesions (e.g., retinal thrombosis), Headache/migraine, Bleeding irregularities, Depression |
| Food/Dietary | No specific food restrictions; however, grapefruit juice may increase estrogen levels slightly (theoretical). Maintain consistent intake of folate-rich foods as oral contraceptives may lower folate levels. Avoid St. John's wort (herbal) as it reduces contraceptive efficacy. |
| Clinical Pearls | MODICON 21 (norethindrone/ethinyl estradiol) is a monophasic oral contraceptive. Administer starting on day 1 of menstrual period (Sunday start or day 1 start). Breakthrough bleeding is common in first cycles; sustained bleeding warrants evaluation. Missed dose protocol: if one pill is missed, take it ASAP and continue schedule; if two or more missed, use backup contraception for 7 days. Advise against smoking due to increased thrombotic risk, especially in women over 35. Assess for contraindications: history of DVT/PE, migraine with aura, breast cancer, liver disease, uncontrolled hypertension, etc. Drug interactions: rifampin, anticonvulsants (phenytoin, carbamazepine), St. John's wort may reduce efficacy. |
| Patient Advice | Take one pill daily at the same time each day for 21 days, then 7 days off. · If you miss a pill, follow the missed dose instructions in the package insert. · Use backup contraception (e.g., condoms) if you miss two or more pills. · Do not smoke while taking this medication; smoking increases risk of blood clots. · Report any sudden severe headache, chest pain, leg swelling, or vision changes immediately. · You may experience irregular bleeding, nausea, or breast tenderness initially. · This medication does not protect against sexually transmitted infections. · Check with your doctor before starting any new medications, including herbal supplements. |
Loading safety data…